ADX-324(Tenacia)

N/A

Report date: 2026/04/08 20:02:35
NME

Base Information

Drug NameADX-324(Tenacia)
Drug Alias NameADX-324ADX324
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionPlasma kallikrein inhibitors
TargetsPlasma kallikrein
Therapy Area/IndicationsAngioedemas, Hereditary
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesYuanyi Biotechnology (Shanghai) Co., Ltd.
China Registration ClassN/A

Develop Information

Active CompaniesYuanyi Biotechnology (Shanghai) Co., Ltd.Tenacia Biotechnology (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsAngioedemas, Hereditary
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A